NICE Again Rejects Xarelto, This Time In DVT Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. cost watchdog NICE asks for further data on use of Bayer's Xarelto for the treatment and prevention of deep vein thrombosis, having made similar demands at the start of the year on its use in atrial fibrillation.